BELITE BIO INC - ADR (BLTE) Stock Price, Quote, News and Overview
NASDAQ:BLTE - Nasdaq - US07782B1044 - ADR - Currency: USD
BLTE Quote, Performance and Key Statistics
61.81
-3.14 (-4.83%)
The current stock price of BLTE is 61.81 USD. In the past month the price increased by 3.58%. In the past year, price increased by 26.38%.
BLTE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 43.54 | 666.46B | ||
| JNJ | JOHNSON & JOHNSON | 17.78 | 428.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.91 | 246.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.05 | 243.41B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 241.88B | ||
| MRK | MERCK & CO. INC. | 11.03 | 213.26B | ||
| PFE | PFIZER INC | 7.47 | 143.95B | ||
| SNY | SANOFI-ADR | 11.33 | 122.41B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.18 | 98.38B | ||
| GSK | GSK PLC-SPON ADR | 8.75 | 79.94B | ||
| ZTS | ZOETIS INC | 25.03 | 69.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.67 | 48.00B |
Related stock screener links
About BLTE
Company Profile
Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
Company Info
BELITE BIO INC - ADR
12750 High Bluff Drive Suite 475
San Diego CALIFORNIA US
Employees: 25
Phone: 18582466240
BELITE BIO INC - ADR / BLTE FAQ
What is the stock price of BELITE BIO INC - ADR today?
The current stock price of BLTE is 61.81 USD. The price decreased by -4.83% in the last trading session.
What is the ticker symbol for BELITE BIO INC - ADR stock?
The exchange symbol of BELITE BIO INC - ADR is BLTE and it is listed on the Nasdaq exchange.
On which exchange is BLTE stock listed?
BLTE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BELITE BIO INC - ADR stock?
11 analysts have analysed BLTE and the average price target is 95.63 USD. This implies a price increase of 54.71% is expected in the next year compared to the current price of 61.81. Check the BELITE BIO INC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BELITE BIO INC - ADR worth?
BELITE BIO INC - ADR (BLTE) has a market capitalization of 2.03B USD. This makes BLTE a Mid Cap stock.
How many employees does BELITE BIO INC - ADR have?
BELITE BIO INC - ADR (BLTE) currently has 25 employees.
What are the support and resistance levels for BELITE BIO INC - ADR (BLTE) stock?
BELITE BIO INC - ADR (BLTE) has a support level at 58.55 and a resistance level at 61.82. Check the full technical report for a detailed analysis of BLTE support and resistance levels.
Should I buy BELITE BIO INC - ADR (BLTE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLTE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLTE, evaluating the profitability, health, valuation and growth aspects
- BELITE BIO INC - ADR (BLTE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BELITE BIO INC - ADR (BLTE) Sales and EPS estimates to see what analysts future expectations are.
- BELITE BIO INC - ADR (BLTE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BELITE BIO INC - ADR (BLTE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BELITE BIO INC - ADR (BLTE) Stock Chart to make your own analysis
- BELITE BIO INC - ADR (BLTE) Latest news and press-releases to stay up to date.
Does BELITE BIO INC - ADR (BLTE) stock pay dividends?
BLTE does not pay a dividend.
What is the Price/Earnings (PE) ratio of BELITE BIO INC - ADR (BLTE)?
BELITE BIO INC - ADR (BLTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.55).
What is the Short Interest ratio of BELITE BIO INC - ADR (BLTE) stock?
The outstanding short interest for BELITE BIO INC - ADR (BLTE) is 1.11% of its float. Check the ownership tab for more information on the BLTE short interest.
BLTE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BLTE. When comparing the yearly performance of all stocks, BLTE is one of the better performing stocks in the market, outperforming 76.2% of all stocks.
BLTE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLTE. While BLTE has a great health rating, there are worries on its profitability.
BLTE Financial Highlights
Over the last trailing twelve months BLTE reported a non-GAAP Earnings per Share(EPS) of -1.55. The EPS decreased by -26.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.71% | ||
| ROE | -26.69% | ||
| Debt/Equity | 0 |
BLTE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BLTE. The Buy consensus is the average rating of analysts ratings from 11 analysts.